Bristol-Myers Squibb’s Bright Future Unfolds Beyond Q2 2023 Turmoil (NYSE:BMY)

Аннотация 3d рендеринга белого подиума стенд, пьедестал победителя на розовой пастельные фон сцены. Симпатичный мультфильм ракетостроение

Mananya Kaewthawee/iStock via Getty Images

On July 27, before the market opened, Bristol-Myers Squibb (NYSE:BMY) released its Q2 2023 financial results, which, while failing to beat analysts’ expectations, were able to demonstrate that demand for Yervoy, Opdualag, and Breyanzi is growing faster than many

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *